Entering text into the input field will update the search result below

INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors

Apr. 05, 2022 4:20 AM ETINmune Bio, Inc. (INMB)BIIB18 Comments


  • INKmune therapy, NK cell therapy, was shown to activate NK cells that killed off >70% of NK resistant tumor cells in an in vitro assay in an MDS patient.
  • INKmune approach will be used to activate dormant NK cells and allow them to kill off cancer cells; additional indications include ovarian cancer, renal cell carcinoma and nasopharyngeal carcinoma.
  • XPro is in a phase 2 study for the treatment of mild Alzheimer's Disease patients; Results from this study expected by 2nd half of 2023.
  • The global Alzheimer's Disease market could reach $25 billion by 2027.
  • I do much more than just articles at Biotech Analysis Central: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »

Sterile Modern Factory: Professionals in Coveralls, Masks Working on CNC Machinery. Medical Electronics Manufacturing Laboratory with High Tech Robot Arm Production Line and Contemporary Equipment

gorodenkoff/iStock via Getty Images

INmune Bio, Inc. (NASDAQ:INMB) is a great speculative biotech play to look into. The reason why I make this claim is because it has two potentially good approaches for targeting multi-billion dollar market opportunities. The

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis profile picture

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (18)

johnny inca profile picture
Thoughts now?
Reminds me of $GNCA
Jacob Braun profile picture
My investment firm Braun Capital is interviewing leadership of the company for our YouTube channel. Do you have any questions you want us to ask? Also, I would love to have you on the channel to talk INmune Bio.
@Jacob Braun seems like they are running 2 parallel studies. The MCI trial (data due 1h'23), and the Mild AD trial (data due 2n'23). Whats the difference between the two trials?
Jacob Braun profile picture
@irongate I will write down this question. As mentioned above, open invite to come on the channel anytime you want.
@irongate Physiology of MCI and trajectory is different than mild AD. There is a continuum of disease, but predictability in mild AD is reasonably clear, and more complicated in mci patients. Biomarkers are also a bit different, if I remember correctly.
Carl Kestens profile picture
Fixing neurodegeneration is all about the (micro)glia:

Load at $5, but not higher.
Carl Kestens profile picture
Great work! INKmune will inevitably partner, and I don't think that will take too long.

Check out my latest blog:
i wonder about partnerships. Front center is ABBV's Humera thats about to come up against significant competition. INMB could give them a Humeria with a significantly better safety profile.
here is a good overview on the NK cell program, and why it may be vastly superior to IPSC therapies from the likes of FATE and IPSC www.sec.gov/...
jondoeuk profile picture
@AlphaChimp For solid tumours, FATE has developed FT536 [1], which is designed to overcome MICA/B shedding and should promote a cytotoxic response. If that does show activity, there are many ways they could improve it, including better trafficking to sites of disease [2], and increase persistence as well as cytotoxicity [3]. Another would be adding an HDAC inhibitor [4].

Moving to AML, have presented clinical data [5]. Additional data from FT538 (+/- daratumumab) could be presented at ASH near the end of the year.


1 jitc.bmj.com/...

2 link.springer.com/...
3 www.cell.com/...
4 aacrjournals.org/...

5 www.globenewswire.com/...
@jondoeuk great. However only INKmune has shown memory-like NK cells, and durability of NK cells. Avidity of their primed natural NK cells is also superior to the IPSC artifical NK cells.
jondoeuk profile picture
@AlphaChimp Others have shown that, but what matters is that it translates into clinical benefit for patients with higher-risk MDS and/or R/R AML.

Speaking generally, it's known that MICA/B can be shed, resulting in escape from NK cell recognition [1]. In this paper, the authors looked at soluble MICA (shed into the serum) and found it was associated with reduced survival [2]. In another, a different group showed the same [3].

So recognition is one of many hurdles to overcome. Others are immunosuppressive tumour microenvironments, which results in disfunction and exhaustion. Also, evasion via different inhibitory receptors, such as HLA-E. Based on this, I favour a (highly) engineered cell based approach.

That said, the treatment INMB is developing could still play a role, just in a different patient population, like those at a (very) high risk of relapse after standard of care.

1 www.nature.com/...

2 aacrjournals.org/...
3 www.cancercommun.com/...
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About INMB

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on INMB

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.